Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Prospective assessment of histological serial sectioning of pelvic lymph nodes in prostate cancer: a cost-benefit analysis.

Schilling D, Hennenlotter J, Gakis G, Schwentner C, Kuehs U, Stenzl A, Sotlar K.

BJU Int. 2012 Sep;110(6 Pt B):E166-71. doi: 10.1111/j.1464-410X.2012.10928.x.

2.

Histological step sectioning of pelvic lymph nodes increases the number of identified lymph node metastases.

Engvad B, Poulsen MH, Staun PW, Walter S, Marcussen N.

Virchows Arch. 2014 Jan;464(1):45-52. doi: 10.1007/s00428-013-1510-5.

PMID:
24259030
3.

Quantification of tumor cell burden by analysis of single cell lymph node disaggregates in metastatic prostate cancer.

Schilling D, Hennenlotter J, Sotlar K, Kuehs U, Senger E, Nagele U, Boekeler U, Ulmer A, Stenzl A.

Prostate. 2010 Jul 1;70(10):1110-8. doi: 10.1002/pros.21145.

PMID:
20503396
4.

Periprostatic lymph node metastasis in prostate cancer and its clinical significance.

Deng FM, Mendrinos SE, Das K, Melamed J.

Histopathology. 2012 May;60(6):1004-8. doi: 10.1111/j.1365-2559.2011.04117.x.

PMID:
22373012
5.

The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.

Schiavina R, Manferrari F, Garofalo M, Bertaccini A, Vagnoni V, Guidi M, Borghesi M, Baccos A, Morselli-Labate AM, Concetti S, Martorana G.

BJU Int. 2011 Oct;108(8):1262-8. doi: 10.1111/j.1464-410X.2010.10016.x.

6.
7.

Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?

Gazquez C, Ribal MJ, Marín-Aguilera M, Kayed H, Fernández PL, Mengual L, Alcaraz A.

BJU Int. 2012 Nov;110(9):1310-6. doi: 10.1111/j.1464-410X.2012.11025.x.

8.

Reliability of preoperative diagnostics and location of lymph node metastases in presumed unilateral prostate cancer.

Weckermann D, Holl G, Dorn R, Wagner T, Harzmann R.

BJU Int. 2007 May;99(5):1036-40.

9.

Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.

Heck MM, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, Mollenhauer M, Schuster T, Autenrieth M, Kübler H, Maurer T, Thalgott M, Herkommer K, Gschwend JE, Nawroth R.

Eur Urol. 2014 Aug;66(2):222-9. doi: 10.1016/j.eururo.2013.02.007.

PMID:
23465520
10.
11.

[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.

Poulsen MH, Bouchelouche K, Høilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, Marcussen N, Svolgaard N, Vach W, Geertsen U, Walter S.

BJU Int. 2012 Dec;110(11):1666-71. doi: 10.1111/j.1464-410X.2012.11150.x.

12.

The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer.

Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Märkl B, Gordijn R, Harzmann R.

Eur Urol. 2003 Feb;43(2):132-6; discussion 137.

PMID:
12565770
13.
14.

Detecting lymph nodes metastasis in prostate cancer through extended vs. standard laparoscopic pelvic lymphadenectomy.

Arenas LF, Füllhase C, Boemans P, Fichtner J.

Aktuelle Urol. 2010 Jan;41 Suppl 1:S10-4. doi: 10.1055/s-0029-1224663.

PMID:
20094944
15.

Nodal occult metastases in intermediate- and high-risk prostate cancer patients detected using serial section, immunohistochemistry, and real-time reverse transcriptase polymerase chain reaction: prospective evaluation with matched-pair analysis.

Schiavina R, Capizzi E, Borghesi M, Vagnoni V, Romagnoli D, Rocca GC, Giunchi F, D'Errico A, De Giovanni A, Rizzi S, Brunocilla E, Martorana G, Fiorentino M.

Clin Genitourin Cancer. 2015 Apr;13(2):e55-64. doi: 10.1016/j.clgc.2014.08.004.

PMID:
25212578
17.

Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.

Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, Oyen R, Ameye F, Bogaerts K, Haustermans K, Van Poppel H.

Eur Urol. 2011 Jul;60(1):125-30. doi: 10.1016/j.eururo.2011.01.015.

PMID:
21292388
18.

Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen.

Moul JW, Lewis DJ, Ross AA, Kahn DG, Ho CK, McLeod DG.

Urology. 1994 Jan;43(1):68-73. Review.

PMID:
7506855
19.

Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer.

Ferrari AC, Stone NN, Eyler JN, Gao M, Mandeli J, Unger P, Gallagher RE, Stock R.

J Natl Cancer Inst. 1997 Oct 15;89(20):1498-504.

PMID:
9337346
20.

Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer.

Birkhäuser FD, Studer UE, Froehlich JM, Triantafyllou M, Bains LJ, Petralia G, Vermathen P, Fleischmann A, Thoeny HC.

Eur Urol. 2013 Dec;64(6):953-60. doi: 10.1016/j.eururo.2013.07.032.

PMID:
23916692

Supplemental Content

Support Center